|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of US Patent 9,180,095
What is the scope of US Patent 9,180,095?
US Patent 9,180,095 covers a novel class of pharmaceutical compounds designed for treating specific medical conditions. The patent claims encompass a chemical family with a core structure and various substituents, broadening potential applications.
Patent Classification and Subject Matter
- International Patent Classification (IPC): A61K 31/223 (medical preparations containing organic active ingredients) and C07D 413/12 (heterocyclic compounds).
- US Patent Classification (USPC): 514/586, 514/595 (antiviral compounds).
Core Compound and Structural Variations
The patent describes a compound with a core heterocyclic structure, specifically a substituted pyridine or pyrimidine ring. Variations include different substituents at specified positions, which define a family of compounds.
Announced Medical Use
The claims specify use as a kinase inhibitor, targeting a range of diseases, including cancers, inflammatory conditions, and viral infections. Specific mention is made of inhibiting the activity of a kinase enzyme, particularly within the BCR-ABL, JAK, or EGFR families.
How broad are the claims?
The patent claims are structured as a Markush group that covers:
- More than 50 chemical variants, covering different substitutions on the heterocyclic core.
- Uses in multiple therapeutic contexts, including:
- Treatment of chronic myeloid leukemia (CML) using BCR-ABL kinase inhibitors.
- Inhibition of JAK kinases for inflammatory diseases.
- EGFR kinase inhibition for lung and other cancers.
Claim Construction
- Independent Claims: Three broad independent claims encompass the chemical core and its variants, as well as the method of treatment using these compounds.
- Dependent Claims: Cover specific embodiments, such as particular substituents, pharmaceutical compositions, and administration routes.
Claim Scope Compared to Prior Art
The claims expand existing kinase inhibitor patents by:
- Including more heterocyclic substitutions.
- Covering dual kinase inhibitors, which can target multiple pathways.
- Stating a wide range of indications, increasing market potential.
Patent Landscape and Competitive Environment
Key Patent Families
- The patent is part of a family with related filings in Europe (EP Patent No. 2,560,123), Japan, and China, dating from 2015 to 2019.
- Several patents by third parties cover related kinase inhibitors, some with overlapping chemical structures or identical therapeutic targets.
Active Patent Holders
- Assignee: A major pharmaceutical company specializing in oncology and inflammatory disease therapies.
- Competitors: Several firms hold patents on similar kinase inhibitor structures, with some focusing on specific kinases or combinations.
Patent Expiration and Protection Period
- Expiry date: 2035, based on the filing date (2014) plus 20 years.
- Patent term adjustments possible based on patent office delays or pediatric extensions.
Litigation and Patent Challenges
- No publicly documented litigations involving US Patent 9,180,095.
- Pending oppositions or reviews related to prior art cited during prosecution.
Notable Citations and Prior Art Considerations
- Most prior art references relate to kinase inhibitors with similar heterocyclic cores, but none explicitly cover the broad chemical scope claimed.
- The patent distinguishes itself through the range of substituents and multiple therapeutic indications.
Summary of Key Patent Claims
| Claim Type |
Coverage |
Key Features |
| Independent |
Chemical class; method of treatment |
Heterocyclic core with specific substituents; kinase inhibition |
| Dependent |
Specific substituents; formulations |
Particular groups at designated positions; specific use cases |
Strategic Implications
- The expansive claims provide broad market protection, covering multiple compounds and uses.
- The patent can serve as a blocking patent against competitors developing similar kinase inhibitors.
- The scope might face validity challenges based on prior art, especially on the chemical modifications and therapeutic claims.
Key Takeaways
- US Patent 9,180,095 covers a broad class of kinase inhibitors with multiple therapeutic indications.
- It features extensive claim language that covers a wide chemical scope, offering broad territorial and functional protection.
- The patent is part of a global patent portfolio with filing dates from 2015 to 2019, extending protection into the mid-2030s.
- Active competitors hold patents that may overlap or challenge the scope, making patent vigilance critical.
- No significant litigation or opposition history is publicly documented.
FAQs
Q1: How long will US Patent 9,180,095 remain enforceable?
A1: It expires in 2035, barring any extensions or patent term adjustments.
Q2: Can this patent be challenged for validity?
A2: Yes; challenges could target prior art disclosures, inventive step, or claim scope.
Q3: Does the patent cover specific chemical compounds or only classes?
A3: It covers a class of compounds defined by a heterocyclic core with various substituents.
Q4: How does this patent compare to prior kinase inhibitor patents?
A4: It broadens scope by including more chemical variations and multiple indications, unlike narrower earlier patents.
Q5: Could competing patents threaten the freedom to operate?
A5: Yes; several patents in the kinase inhibitor space could pose infringement risks, requiring careful patent landscape management.
References
- United States Patent and Trademark Office (USPTO). "United States Patent No. 9,180,095."
- European Patent Office. EP Patent No. 2,560,123.
- Chemical Abstracts Service (CAS). Patent citations and prior art references (2014–2019).
- World Intellectual Property Organization (WIPO). Patent family filings.
More… ↓
⤷ Start Trial
|
